Skip to main content

Canos

Canos provides liquid biopsy testing for dogs, combining cancer detection with a comprehensive genomic health baseline from a single blood draw. The Origin test analyzes genetics, epigenetics, and cell-free DNA to screen for cancer signals, 346 inherited diseases, traits, and ancestry, with results delivered in about two weeks. Priced at $699 including the veterinary visit, the service also enables ongoing cancer monitoring through its OncoTrack product.

Traction –/10
HQ unknown
3100+ followers
  • Biotechnology
  • Healthcare Technology
  • Pet Technology
Updated 16 days ago

Funding

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Cancer is a leading cause of death in dogs, yet early detection remains challenging because symptoms often appear only after the disease has progressed. Traditional diagnostic approaches may not catch cancer-associated molecular changes until tumors are advanced, limiting treatment options and outcomes.

Solution

Canos provides liquid biopsy testing for dogs, creating a comprehensive genomic health baseline that detects cancer-associated signals in blood. The Origin test analyzes genetics, epigenetics, and cell-free DNA (cfDNA) from a single blood sample to identify cancer signals while also profiling inherited health, physical traits, drug responses, and ancestry. Results are delivered in about two weeks and can be shared with veterinarians. For dogs undergoing cancer treatment, the OncoTrack product enables monitoring of molecular residual disease and changes through treatment and follow-up, allowing for more informed care decisions.

Target Audience

Primary customers are dog owners who want proactive health monitoring for their pets, as well as veterinarians seeking genomic data to inform cancer detection and treatment decisions.

Features

  • Cancer detection through cfDNA methylation and epigenetic analysis from a blood draw
  • Genetic panel covering 346 inherited diseases, 31 physical traits, 7 drug responses, and ancestry across 321 breeds
  • Genome-wide cfDNA methylation profile banked as a personal reference for future comparisons
  • Immune cell profile providing information about immune cell makeup and immune aging
  • OncoTrack product for tracking molecular residual disease through cancer treatment and follow-up
  • New validated analyses (biological age, organ health, breed health risks) added automatically for founding members at no extra charge
  • Multiple blood collection options including group draw days, mobile vet at home, or shipping a collection kit anywhere in the US
This profile is AI-generated and may contain inaccuracies.